A5007674532- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Island Studies and Pacific Affairs
- Acute Myeloid Leukemia Research
- Protein purification and stability
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Mass Spectrometry Techniques and Applications
- Advanced Breast Cancer Therapies
- Pharmaceutical studies and practices
- Cancer therapeutics and mechanisms
- Chemical Synthesis and Analysis
- Global Health and Epidemiology
- Economic and Financial Impacts of Cancer
- Cell Adhesion Molecules Research
- International Development and Aid
Bayer (United States)
2023
Seagen (United States)
2014-2021
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, there evidence that its expression increased leukemic relative normal hematopoietic stem cells, which makes it an attractive target antibody-based therapy. Here, we report generation preclinical characterization SGN-CD123A, antibody-drug conjugate using...
Antibody-drug conjugates (ADCs) are protein therapeutics in which a target specific monoclonal antibody (mAb) is conjugated with drug molecules. The manufacturing of ADCs involves additional conjugation steps, carried out on the parent mAbs, and it important to evaluate how process impacts conformation dynamics mAb. Here, we present comparative study interchain cysteine linked IgG1 corresponding mAb by hydrogen/deuterium exchange mass spectrometry (HDX-MS). We found that ∼90% primary...
We present the results of a hydrogen/deuterium exchange mass spectrometric (HDX-MS) investigation an antibody-drug conjugate (ADC) comprised drug-linkers conjugated to cysteine residues that have been engineered into heavy chain (HC) fragment crystallizable (Fc) domain at position 239. A side-by-side comparison HC Ser239 wild type (wt) monoclonal antibody (mAb) and Cys239 mAb indicates site directed mutagenesis has no impact on HDX kinetics mAb. According crystal structure homologous...
Establishing and maintaining conformational integrity of monoclonal antibodies (mAbs) antibody-drug conjugates (ADCs) during development manufacturing is critical for ensuring their clinical efficacy. As presented here, we applied site-specific carboxyl group footprinting (CGF) localized interrogation mAbs. The approach relies on covalent labeling that introduces glycine ethyl ester tags onto solvent-accessible side chains protein carboxylates. Peptide mapping used to monitor the kinetics...
6611 Background: The 21 st Century Cures Act in 2016 enhanced the FDA’s ability to include use of real-world data (RWD) and consideration RWE development approval new medical products. Currently, limited assessments FDA approved oncology product reviews exist literature. This study was conducted determine how used decisions for drug approvals between 2015 2022. Methods: A systematic review submission documents labels available on website from 2020 2022, addition an exhaustive manual search...
<p>Gating strategy, primary AML cytotoxicity assay,additional cell liens for pH2AX assay and caspase assay, h7G3ec antibody sequence</p>
<div>Abstract<p>Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, there evidence that its expression increased leukemic relative normal hematopoietic stem cells, which makes it an attractive target antibody-based therapy. Here, we report generation preclinical characterization SGN-CD123A,...
<p>Gating strategy, primary AML cytotoxicity assay,additional cell liens for pH2AX assay and caspase assay, h7G3ec antibody sequence</p>
<div>Abstract<p>Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, there evidence that its expression increased leukemic relative normal hematopoietic stem cells, which makes it an attractive target antibody-based therapy. Here, we report generation preclinical characterization SGN-CD123A,...